Thermo Fisher executive Michel Lagarde exercises options, sells 22,046 shares

Thermo Fisher Scientific executive Michel Lagarde reported option exercises and a stock sale.

Rhea-AI Filing Summary

Thermo Fisher Scientific executive Michel Lagarde reported option exercises and a stock sale. On December 4, 2025, he exercised stock options for 18,637 shares of common stock at an exercise price of $105.17 per share and another 22,046 shares at an exercise price of $132.66 per share. On the same day, he sold 22,046 shares of Thermo Fisher Scientific common stock at a weighted average price of $563.56 per share, with individual sale prices ranging from $563.38 to $564.20.

After these transactions, Lagarde beneficially owned 84,116.909 shares of Thermo Fisher Scientific common stock in direct form. The options exercised had previously vested in scheduled installments in 2017, 2018, 2019 and 2020, and following the reported exercises, the specific option grants referenced now show 0 derivative securities remaining.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 5 txns

Insider Lagarde Michel

Role Executive Vice President & COO

Sold 22,046 shs ($12.42M)

Approx. gross sale proceeds $12.42M

Approx. exercise cost $4.88M

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	22,046	$0.00	$0.00
Exercise	Stock Option (Right to Buy)	18,637	$0.00	$0.00
Exercise	Common Stock	18,637	$105.17	$1.96M
Exercise	Common Stock	22,046	$132.66	$2.92M
Sale	Common Stock	22,046	$563.56	$12.42M

Holdings After Transaction: Stock Option (Right to Buy) — 0 contracts (Direct); Common Stock — 84,116.909 shares (Direct)

Footnotes (3)

1. F1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $563.38 to $564.20, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
2. F2. The option vested in three equal installments on March 23, 2018, 2019 and 2020.
3. F3. The option vested in two equal installments on August 29, 2017 and 2020.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Thermo Fisher Scientific (TMO) report for Michel Lagarde?

Michel Lagarde, Executive Vice President & COO of Thermo Fisher Scientific (TMO), reported exercising stock options and selling common shares on December 4, 2025, as disclosed on a Form 4.

How many Thermo Fisher (TMO) shares did Michel Lagarde sell and at what price?

Michel Lagarde sold 22,046 shares of Thermo Fisher common stock at a weighted average price of $563.56 per share, with individual trades between $563.38 and $564.20.

How many Thermo Fisher (TMO) stock options did Michel Lagarde exercise and at what prices?

He exercised options for 18,637 shares at an exercise price of $105.17 per share and 22,046 shares at an exercise price of $132.66 per share on December 4, 2025.

How many Thermo Fisher Scientific (TMO) shares does Michel Lagarde own after the reported Form 4 transactions?

Following the reported transactions, Michel Lagarde beneficially owned 84,116.909 shares of Thermo Fisher Scientific common stock in direct ownership.

What is Michel Lagarde’s role at Thermo Fisher Scientific (TMO) according to this Form 4?

Michel Lagarde is identified as an Officer of Thermo Fisher Scientific, serving as Executive Vice President & COO.

When did the Thermo Fisher (TMO) stock options exercised by Michel Lagarde originally vest?

One stock option grant vested in three equal installments on March 23, 2018, 2019 and 2020, and another vested in two equal installments on August 29, 2017 and 2020.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/05/2025 - 04:40 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lagarde Michel

(Last) (First) (Middle)

168 THIRD AVENUE

(Street)

WALTHAM MA 02451

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
THERMO FISHER SCIENTIFIC INC. [ TMO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Vice President & COO

3. Date of Earliest Transaction (Month/Day/Year)
12/04/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/04/2025		M		18,637	A	$105.17	84,116.909	D
Common Stock	12/04/2025		M		22,046	A	$132.66	106,162.909	D
Common Stock	12/04/2025		S		22,046	D	$563.56(1)	84,116.909	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$132.66	12/04/2025		M			22,046	(2)	03/23/2027	Common Stock	22,046	$0	0	D
Stock Option (Right to Buy)	$105.17	12/04/2025		M			18,637	(3)	07/20/2026	Common Stock	18,637	$0	0	D

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $563.38 to $564.20, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

2. The option vested in three equal installments on March 23, 2018, 2019 and 2020.

3. The option vested in two equal installments on August 29, 2017 and 2020.

	/s/ Melodie T. Morin, Attorney-in-Fact for Michel Lagarde	12/05/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.